Interleukin-33 induces urokinase in human endothelial cells--possible impact on angiogenesis

J Thromb Haemost. 2014 Jun;12(6):948-57. doi: 10.1111/jth.12581.

Abstract

Background: Urokinase-type plasminogen activator (u-PA) plays a pivotal role in extracellular proteolysis and is thought to be critically involved in the modulation of angiogenesis. Interleukin (IL)-33 is a member of the IL-1 cytokine family, which is thought to act as danger signal that is released from cells after injury. IL-33 is involved in the pathogenesis of various inflammatory diseases and previously was shown to induce angiogenesis and inflammatory activation of endothelial cells.

Objective: We investigated the impact of IL-33 on u-PA in endothelial cells as a new possible function for IL-33.

Methods and results: We could demonstrate that IL-33 upregulated u-PA mRNA expression and protein production in human coronary artery and human umbilical vein endothelial cells in a time- and concentration-dependent manner via interaction with its receptor ST2 and activation of the nuclear factor-κB pathway but independent of autocrine IL-1-induced effects. The hydroxymethylglutaryl-coenzyme A reductase inhibitor simvastatin abrogated the IL-33-induced increase in u-PA, thus providing further evidence for pleiotropic effects of statins. IL-33 induced u-PA-dependent capillary-like tube formation and vessel sprouting. In human carotid atherosclerotic plaques (n = 16), u-PA mRNA positively correlated with IL-33 mRNA expression (r = 0.780, P < 0.001). Furthermore, IL-33 and u-PA protein were detected in endothelial cells in these samples using fluorescence immunohistochemistry.

Conclusions: We hypothesize that IL-33, representing a danger signal that is released after tissue damage, in addition to its role in the inflammatory activation of endothelial cells, is involved in u-PA-driven angiogenesis, a process that has been shown before to be linked to inflammation in various pathologies.

Keywords: angiogenic factor; endothelial cells; interleukin-33, human; protein degradation; urokinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inducing Agents / pharmacology*
  • Carotid Arteries / metabolism
  • Carotid Arteries / pathology
  • Carotid Artery Diseases / genetics
  • Carotid Artery Diseases / metabolism
  • Carotid Artery Diseases / pathology
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects*
  • Endothelial Cells / enzymology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / enzymology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Interleukin-1 Receptor-Like 1 Protein
  • Interleukin-33
  • Interleukins / genetics
  • Interleukins / metabolism
  • Interleukins / pharmacology*
  • NF-kappa B / metabolism
  • Neovascularization, Physiologic / drug effects*
  • Plaque, Atherosclerotic
  • RNA Interference
  • RNA, Messenger / metabolism
  • Receptors, Cell Surface / agonists
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / metabolism
  • Recombinant Proteins / pharmacology
  • Signal Transduction / drug effects
  • Simvastatin / pharmacology
  • Time Factors
  • Transfection
  • Up-Regulation
  • Urokinase-Type Plasminogen Activator / genetics
  • Urokinase-Type Plasminogen Activator / metabolism*

Substances

  • Angiogenesis Inducing Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • IL1RL1 protein, human
  • IL33 protein, human
  • Interleukin-1 Receptor-Like 1 Protein
  • Interleukin-33
  • Interleukins
  • NF-kappa B
  • RNA, Messenger
  • Receptors, Cell Surface
  • Recombinant Proteins
  • Simvastatin
  • Urokinase-Type Plasminogen Activator